Investment Analysts’ Weekly Ratings Changes for Praxis Precision Medicines (PRAX)

A number of research firms have changed their ratings and price targets for Praxis Precision Medicines (NASDAQ: PRAX):

• 5/26/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by HC Wainwright. They now have a $1,245.00 price target on the stock.
• 5/20/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by BTIG Research. They now have a $843.00 price target on the stock.
• 5/13/2026 – Praxis Precision Medicines had its price target raised by Truist Financial Corporation from $700.00 to $715.00. They now have a “buy” rating on the stock.
• 5/8/2026 – Praxis Precision Medicines was given a new $420.00 price target by Deutsche Bank Aktiengesellschaft.
• 5/8/2026 – Praxis Precision Medicines had its price target raised by Wedbush from $130.00 to $166.00. They now have an “underperform” rating on the stock.
• 5/8/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by BTIG Research. They now have a $843.00 price target on the stock.
• 5/7/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 4/15/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $437.00 price target on the stock.
• 4/14/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $510.00 price target on the stock.
• 4/10/2026 – Praxis Precision Medicines is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $815.00 price target on the stock.
• 4/9/2026 – Praxis Precision Medicines is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating on the stock.
• 4/7/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by HC Wainwright. They now have a $1,245.00 price target on the stock.
• 4/6/2026 – Praxis Precision Medicines had its “buy” rating reaffirmed by BTIG Research. They now have a $843.00 price target on the stock.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.